Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.
Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians has been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics. Everyone at Celularity is passionate about developing innovative treatment options that will make a meaningful difference in patients’ lives.
cell therapy pipeline
ROBERT J. HARIRI, MD, PHD
FOUNDER & CEO
Celgene, Weill Cornell Medicine
XIAOKUI ZHANG, PHD
EVP, CHIEF SCIENTIFIC OFFICER
Celgene, Rockefeller University
NASSIR HABBOUBI, MD
CHIEF MEDICAL OFFICER
JOHN R. HAINES
EVP, CHIEF ADMINISTRATIVE OFFICER
Andiscern, Ionetix, University of Pennsylvania
DAVID C. BEERS
CHIEF FINANCIAL OFFICER
Goldman Sachs, T. Rowe Price
EVP, HUMAN RESOURCES
Celgene, Nabisco, Kraft Foods
BOARD OF DIRECTORS
PETER DIAMANDIS, M.D.
Founder & Executive Chairman, XPRIZE; Executive Founder, Singularity University
HENRI JI, Ph.D.
Co-Founder & CEO, Sorrento Therapeutics
ANDREW PECORA, M.D., F.A.C.P., C.P.E.
Chief Innovation Officer, John Thereur Cancer Center
Chief Executive Officer, Scilex Pharmaceuticals
Former CEO of Apple Inc; Former President of Pepsi-Cola
ANDREW C. VON ESCHENBACH, M.D.
Former Commissioner, United States FDA
Chairman and Chief Executive Officer, Genting Berhad
ROBIN SMITH M.D., M.B.A.
Founder and Board Chair of Stem for Life Foundation; Founder and Board Chair of Cura Foundation
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
January 22, 2020
Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting
December 9, 2019
Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
November 22, 2019
Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs
November 6, 2019
Celularity Enters Lease to Develop Advanced Cell Manufacturing and Research Facility for Commercial-Scale Placental-Derived Allogeneic Cell Therapies
April 11, 2019
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
March 29, 2019
First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting
February 27, 2019
Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado's ClinImmune Labs
August 31, 2018
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
February 15, 2018